anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A few cases of anaphylactic/anaphylactoid reactions are reported in the postmarketing use of MINIVELLE. Involvement of skin (hives, pruritus, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) are noted.

Angioedema involving eye/eyelid, face, larynx, pharynx, tongue and extremity (hands, legs, ankles, and fingers) with or without urticaria requiring medical intervention are reported in the postmarketing use of MINIVELLE. Angioedema involving the tongue, glottis, or larynx, may result in airway obstruction. Do not give MINIVELLE to any woman who develops angioedema during treatment with Minivelle.

Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. Consider whether the benefits of estrogen therapy outweigh the risks in such women.
The target occupancy (TO) of scopolamine at M1 will be evaluated using the radiotracer \[11C\]EMO and positron emission tomography (PET). TO will be measured following a 15-minute IV infusion of 4.0 μg/kg scopolamine in 4-6 anticipated participants.
Provided are a radionuclide-drug conjugate and a pharmaceutical composition and use thereof. Specifically, a precursor of the radionuclide-drug conjugate has a structure represented by formula I, wherein LG represents a targeting ligand; S represents a spacer; L represents a linker; and C represents a chelating agent capable of containing a radionuclide. The radionuclide-drug conjugate can specifically deliver the radionuclide to a target cell. When containing one LG, the drug conjugate can specifically deliver the radionuclide to the target cell. When containing two LGs, the drug conjugate can function in various ways to enhance therapeutic effects and reduce toxic and side effects. Meanwhile, the presence of two LGs also enhances the affinity of the drug conjugate for the target cell, reducing off-target toxicity.
Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m\*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m\*2 on day +1, 10 mg/m\*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.
Hypertrophic scars and keloids are the results of an exaggerated healing process and are often associated with significant patient morbidity. Fractional ablative lasers create microchannels in the skin and penetrate into the substance of the scar, inducing a normal healing response in zones of created damage. Focal delivery of scar-modulating agents into the scar through these microchannels-a process termed laser-assisted drug delivery (LADD)-is a promising and developing treatment modality. In this systematic review, we aim to critically examine the evidence of LADD in the treatment of hypertrophic scars and keloids. The evidence suggests that LADD improves outcomes in hypertrophic scars and keloids. LADD is a more effective treatment modality than the topical application of agents in hypertrophic scars and equally effective as the intralesional injection of agents in keloids. There were few reports of adverse events. Evidence supports the use of LADD as an adjunct to non-surgical measures or a treatment modality to be used before more invasive measures such as surgical excision. However, the quality of evidence supporting this conclusion is inconsistent and lacks power. Additional studies are required to optimize dosages, laser settings, and agent choices for the treatment of these lesions.
Given the recent evidence in the clinical application of regenerative medicine, mostly on integumentary systems, we focused our interests on recent bladder regeneration approaches based on mesenchymal stem cells (MSCs), platelet-rich plasma (PRP), and hyaluronic acid (HA) in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) in humans. IC/BPS is a heterogeneous chronic disease with not-well-understood etiology, characterized by suprapubic pain related to bladder filling and urothelium dysfunction, in which the impairment of immunological processes seems to play an important role. The histopathological features of IC include ulceration of the mucosa, edema, denuded urothelium, and increased detection of mast cells and other inflammatory cells. A deeper understanding of the molecular mechanism underlying this disease is essential for the selection of the right therapeutic approach. In fact, although various therapeutic strategies exist, no efficient therapy for IC/BPS has been discovered yet. This review gives an overview of the clinical and pathological features of IC/BPS, with a particular focus on the molecular pathways involved and a special interest in the ongoing few investigational therapies in IC/BPS, which use new regenerative medicine approaches, and their synergetic combination. Good knowledge of the molecular aspects related to stem cell-, PRP-, and biomaterial-based treatments, as well as the understanding of the molecular mechanism of this pathology, will allow for the selection of the right and best use of regenerative approaches of structures involving connective tissue and epithelia, as well as in other diseases.
Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
This retrospective, single-center, descriptive study was conducted at the Department of Paediatric Neurology between December 2020 and February 2023, and 157 neonates were recruited to determine the factors related to ceasing ASM treatment in infants at a follow-up 2 years. According to the International League Against Epilepsy (ILAE) classification of neonatal seizures and their etiology, patients who were diagnosed with such seizures and received anti-seizure medication within the first 28 days of life were followed until their ASM was ceased after they were discharged from the neonatal intensive care unit. Infants are defined as children aged younger than 12 months. During this stage of neuronal development, the central nervous system is more susceptible to the harmful effects of external factors. Consequently, the investigators have planned to evaluate the study's initial 12-month follow-up results for our group. Afterwards, the infants were divided into two groups: the first group consisted of infants who continued to receive ASM treatment after 12 months of age (referred to as "infants still on ASM after 12 months", n=69); the second group consisted of infants who had stopped ASM treatment before 12 months of age (referred to as "infants who had ceased ASM before 12 months", n=88).
Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
PURPOSE:The title low-molecular fraction which is obtained by collecting a fraction with a specific or lower molecular weight and used as a substituent for bovine serum culture medium. CONSTITUTION:The objective fraction less than 5,000 molecular weight is collected from yeast essence. In cell culture, calf serum or bovine fetus serum has been required as an essential ingredient, but its supply is limited and the substituent has been desired. Yeast essence has not been used in cell culture and they hardly grow even if they are tried to grow. But, it has been found that the low-molecular fraction can reduce the amount of bovine serum by half. The fraction of less than 5,000 molecular weight is obtained by gel filtration, ultrafiltration or cellophane membrane filtration further the fraction can be stored for a long period time by freeze-drying.
Readily available over-the-counter (OTC) medication for symptomatic relief and appropriate oral hydration can be health saving measures of great convenience for those affected by enteric bacterial and viral infections. BSS is a non-proprietary monograph product that is available in the USA and abroad, over-the-counter (OTC). Of all OTC medications for traveller's diarrhea (TD), bismuth subsalicylate (BSS) has the greatest antimicrobial activity against pathogenic bacteria .BSS has also exhibited significant inhibition on viral invasion of host cells and viral efficacy. Both BSS and bismuth oxychloride (BiOCl, which is formed in the stomach after ingestion of BSS) at low concentration (0.004-0.13mg/mL) significantly reduced norovirus (NoV) RNA levels, suggesting an in vivo antiviral mechanism. BSS has also been shown to have antiviral activity since it inhibited replication of 4 strains of rotavirus in tissue culture cells and caused a dose-dependent reduction in the growth of several enteric viruses.

Historically, BSS has been indicated and effectively used for the treatment of TD or enteric infection, mainly when vomiting occurs. Although the safety and efficacy of BSS is well known, some of the research done with BSS resides within the industry and have not been published. We have recently completed an extensive meta-analysis using unpublished clinical studies regarding BSS safety and efficacy. Meta-analyses of randomized controlled clinical trials were performed with studies specifically designed to capture prevention of manifestation and relief of diarrhea.
Apply a thin layer of Clobetasol Propionate Ointment USP to the affected skin areas twice daily and rub in gently and completely. (See INDICATIONS AND USAGE.)

Clobetasol Propionate Ointment USP is a super-high potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks, and amounts greater than 50 g/week should not be used.

As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

Clobetasol Propionate Ointment USP should not be used with occlusive dressings.
The invention aims to provide two terphenylzidioxazine derivatives and applications thereof. The two terphenylzidioxazine derivatives provided by the invention are compounds shown in formulas I and II. Two new sarcoviolin compounds in the invention can efficiently suppress the activity of alpha-glucosidase, thereby improving the control on type II diabetes. Meanwhile, Animal experiments also show that the two new sarcoviolin compounds can effectively reduce the blood glucose of animals. The compounds disclosed by the invention are derived from edible fungi, so that the compounds have a certain secure base. In conclusion, the two new sarcoviolin compounds in the invention have various market application values of developing alpha-glycosidase inhibitors, preparing drugs for preventing and treating type II diabetes, preparing foods or functional health-care foods, and the like.
The most important property of a drug dosage is its ability to deliver the active ingredient to the site of action in a quantity sufficient to exert the expected pharmacological effect. This ability is known as bioavailability. Methylprednisolone is a drug with wide clinical use in patients with inflammatory pathologies (infectious or non-infectious). The main routes of administration are oral and intravenous. The intranasal route could be one more effective, less invasive that would allow to obtain a faster therapeutic concentration and in greater concentration in the lungs and in the central nervous system than the intravenous route, maintaining very similar systemic concentrations to those achieved intravenously. For these reasons, it is important to know the bioavailability of methylprednisolone administered by this route in order to establish the best dosing regimen. The pilot study is of an exploratory nature (descriptive, comparative or informative), whose objective is to know the pharmacokinetic characteristics of a new route of administration of a drug in the study population to establish the pharmacokinetic parameters, and the comparison between the intranasal bioavailability against the intravenous administration by determining confidence intervals and calculating one-sided double t of Scuirmann.

Objetive: To evaluate the bioavailability of methylprednisolone in healthy subjects of both genders, with administration intranasally versus intravenous dose of 1 ml of methylprednisolone sodium succinate equivalent to 62.5 mg of methylprednisolone.
PURPOSE: To identify the bioenergy and biological vibration activity of water within a short time by projecting electromagnetic radiation having a specific wavelength on water to be investigated housed in a light pervious inactive material container and measuring the intensity change of a steady wave of pulsation. CONSTITUTION: A small amt. of water to be investigated is put in a test tube pref. composed of a vitreous material and proper electromagnetic radiation having a predetermined wavelength within a visible range is projected on the water to be investigated. The change of the activity response of water (the activity in the vibration frequency of water) of the intensity of a steady wave of pulsation is measured at the intermediate position of the radial artery of an operator and/or other person on the spot. This test is repeated with respect to several kinds of different wavelengths within a visible or resonant radiation range to identify the bioenergy and biological vibration frequency activity or effect of water.
The study proposes two specific aims Aim 1 will determine if blocking enteric neuronal signaling will alter: a) circulating levels of nutrient substrates and secretion of hormones that regulate nutrient metabolism; and b) glucose and fatty acid absorption, production, and utilization.

Obese (BMI = 30-50 kg/m2) subjects will be studied. The topical anesthetic benzocaine will be infused into the duodenum prior to infusion of glucose and oleic acid into the duodenum. Duodenal infusions with a naso-intestinal feeding tube will circumvent the confounding effects of gastric emptying on the metabolic responses to a meal. Substrates (glucose, free fatty acids), and lipoproteins) and hormones will be measured by standard biochemical and immunological methods. Aim 2 will determine if enteric neural signals regulate appetite. The studies will be carried out in both lean and obese humans and the procedure will be performed as described above. In addition, the subjects will be asked to use a visual analog scale to estimate their level of appetite before, during and after enteral infusions.
NEW MATERIAL:HS-2 having the following physical and chemical properties. Property: strongly hydroscopic white-light brown rubbery substance. Molecular formula: C24H48O11S2. Elemental analysis (%): C 47.04 H 8.55. Melting point: not showing a clear melting point. Color reaction: positive in Bromocresol Green reaction, iodine reaction and anisaldehyde reaction and negative in 2,4- dinitrophenylhydrazine reaction, FeCl3 reaction and Dragendorff's reaction. Solubility: soluble in alkali water, slightly soluble in neutral water and insoluble in methanol and chloroform, etc. USE:A vasodilator and antihypertensive agent. PREPARATION:A bacterium such as Actinoplanes ferrugineus ATCC 29868 belonging to the genus Actinoplanes is cultured at 20-40 deg.C at neutral pH for 3-15 days.
An extraction method of abalone polysaccharide characterized in that abalone meat (including organs) is obtained by removing abalone shell, broken the wall with a tissue mincer, uniformly mixed with water, extracted at 20 to 80 °C for 2 to 6h, and separated by centrifugation, the insoluble substance is repeatedly extracted for 1 to 2 times by again adding water, and the supernatant is combined. The extract is concentrated to saccharide content of 1.5 to 3.0 percent, precipitated at 0 to 4 °C for 12 to 16h by adding 3 to 4 times volume of 95 percent ethanol, centrifuged and dried by means of vacuum drying or spray drying to give product. The uniform abalone polysaccharide is obtained by purification with Sephadex G-100 or DEAE-Cellulose after removing protein and glucogen. The extraction can also be preformed by alkali extraction, ultrasonic extraction or enzymic extraction. The enzyme extraction can be preformed with a single enzyme, two enzymes, a complex enzyme or the combination thereof. The enzyme used is pepsin, trypsase and so on. There is provided a process of extracting abalone polysaccharide from abalone (especially from abdominal feet and organs thereof), and therefore abalone polysaccharide extraction and separation can be efficiently preformed. There is provided a technical basis for further research due to continuous intensive research on pharmaceutic use of abalone polysaccharide.
(See CLINICAL PHARMACOLOGY, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Acute Otitis Media (total dosage regimen: 30 mg/kg, see DOSAGE AND ADMINISTRATION): Safety and effectiveness in the treatment of pediatric patients with otitis media under 6 months of age have not been established.

Acute Bacterial Sinusitis (dosage regimen: 10 mg/kg on Days 1 to 3): Safety and effectiveness in the treatment of pediatric patients with acute bacterial sinusitis under 6 months of age have not been established. Use of azithromycin for the treatment of acute bacterial sinusitis in pediatric patients (6 months of age or greater) is supported by adequate and well-controlled studies in adults, similar pathophysiology of acute sinusitis in adults and pediatric patients, and studies of acute otitis media in pediatric patients.

Community-Acquired Pneumonia (dosage regimen: 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5): Safety and effectiveness in the treatment of pediatric patients with community-acquired pneumonia under 6 months of age have not been established. Safety and effectiveness for pneumonia due to Chlamydia pneumoniae and Mycoplasma pneumoniae were documented in pediatric clinical trials. Safety and effectiveness for pneumonia due to Haemophilus influenzae and Streptococcus pneumoniae were not documented bacteriologically in the pediatric clinical trial due to difficulty in obtaining specimens. Use of azithromycin for these two microorganisms is supported, however, by evidence from adequate and well-controlled studies in adults.

Pharyngitis/Tonsillitis (dosage regimen: 12 mg/kg on Days 1 to 5): Safety and effectiveness in the treatment of pediatric patients with pharyngitis/tonsillitis under 2 years of age have not been established.

Studies evaluating the use of repeated courses of therapy have not been conducted (see CLINICAL PHARMACOLOGY and ANIMAL TOXICOLOGY).
NEW MATERIAL:The compound of formula I (R1 is OH or lower acyloxy; R2 is benzyl; R1 and R2 may together form benzal group) and its acid addition salt. EXAMPLE:1-Dimethylaminomethyl-2-benzyl-2-hydroxy-cyclohexane. USE:Analgesic. PREPARATION:The exemplified compound of formula IV can be prepared by reacting the compound of formula II with the Grignard reagent of formula III (X is halogen) in an organic solvent (e.g. anhydrous ether) for 1.5-2hr under cooling. The compound of formula II is obtained by the simultaneous reaction of cyclohexanone with paraformaldehyde and dimethylamine in the presence of a small amount of concentrated hydrochloric acid at 60-70 deg.C for 1-2hr.
The present invention relates to a gene, known as CAP43, and its gene product. In particular, the application demonstrates that the CAP43 gene and its gene product are expressed at elevated in certain diseased cells and tissues, such as cancer cells and tissues. The invention therefore provides novel uses for the CAP43 gene and gene product, including novel diagnostic methods for diagnosing diseases, such as cancer, by detected elevated levels of CAP43 expression. Methods are also provided for identifying diseased cells and tissue, particularly cancer cells and tissue, by identifying cells and tissues that express elevated levels of CAP43. Moreover, the invention also provides novel therapeutic methods for treating diseases, such as cancer, by targeting therapeutic compounds to cells expressing CAP43. Pharmaceutical compositions which may be used in such methods of treatment are also provided.
Improvements in fetal ultrasound have allowed for the diagnosis and treatment of fetal diseases in the uterus, often through surgery. However, little attention has been drawn to the assessment of fetal pain. To address this gap, a fetal pain scoring system, known as the Fetal-7 scale, was developed. The present study is a full validation of the Fetal-7 scale. The validation involved 2 steps: 1) 4 fetuses with the indication of surgery were evaluated in 3 conditions perioperatively: acute pain, rest, and under loud sound stimulation. Facial expressions were assessed by 30 raters using screenshots from 4D high-definition ultrasound films; 2) assessment of sensitivity and specificity of the Fetal-7 scale in 54 healthy fetuses and 2 fetuses undergoing acute pain after preoperative anesthetic intramuscular injection. There was high internal consistency with Cronbach's alpha (α) of .99. Intrarater reliability of the Fetal-7 scale (test-retest) calculated by intraclass correlation coefficient was .95, and inter-rater reliability was .99. The scale accurately differentiated between healthy fetuses at rest and those experiencing acute pain (sensitivity of 100% and specificity of 94.4%). The Fetal-7 scale is a valid tool for assessing acute pain-related behavior in third-trimester fetuses and may be of value in guiding analgesic procedures efficacy in these patients. Further research is warranted to explore the presence of postoperative pain in fetuses and its effects after birth. PERSPECTIVE: Recordings with 3-dimensional ultrasound of human fetuses undergoing preoperative anesthetic injections revealed complex facial expressions during acute pain, similar to those collected in newborns. This study presented the validation process and cut-off value of the Fetal-7 scale, paving the way for the study of pain before birth in humans.
The patients in the second group will receive two CBU of high-level HLA matched infusions within a 6-month interval. The high-level match is 4 or more HLA compatibility degree by A, B, DRB1 loci.
80 patients with TRD will be assigned to active or sham rTMS before ECT treatment. Five sessions of active/sham rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session) before ECT (which was active for all patients) started. Then, from the sixth ECT session, an rTMS session will occur the day before each ECT session. Clinical assessment, cognitive assessment and brain imaging (structural MRI, resting state functional MRI, MR spectroscopy) will take place before and after 10 ECT sessions. Clinical, cognitive and neural changes will be compared between both groups after 10 ECT sessions.

The primary outcome will be the response rate after 10 ECT, i.e. the percentage of patients who achieved a reduction of 50% or more from their initial Hamilton Depression Scale score (HAMD-21 items).